Forte Biosciences reports positive results from Phase Ib trial for vitiligo

Forte Biosciences has reported positive results from its double-blind, placebo-controlled Phase Ib trial assessing FB102 for vitiligo. Across all study participants, 34.4% of those treated with FB102 reached FVASI50 and 12.5% attained FVASI75 at week 24. In the intent-to-treat group, FB102 achieved 29.6% mean facial vitiligo area scoring index improvement at week 24. Credit: Prostock-studio / Shutterstock.com. Forte Biosciences has reported positive results from its double-blind, placebo-controlled Phase Ib trial assessing FB102 for vitiligo. The study followed patients through 24 weeks, with a primary endpoint measuring mean per cent improvement from baseline in the facial vitiligo area scoring index (FVASI)…

Source: Clinical Trials Arena